Io Biotech Inc (IOBT) Stock Price, Quote & News

Company Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 70 29 80

Website: www.iobiotech.com

Address:

Ole MaalOees Vej 3, Copenhagen N, Copenhagen, Denmark

Capitulation_0 Dec. 24 at 3:55 PM

$IOBT Seeing uptick in deals for microcaps lately. Company is running out of money, it needs to get a deal done!

0 · Reply

Msnlrainey Dec. 23 at 2:18 PM

$IOBT gotta go up to 1

0 · Reply

Love_To_Learn Dec. 22 at 10:33 PM

$IOBT $APLT *

0 · Reply

Chartwatcher1 Dec. 22 at 8:38 PM

$VSEE looking frisky ...at .46 $MAIA dried out, flat looking for bids....im already loaded $NAK, pop up in the am, with high vol, right up to the top of Wainright price target, been pulling back since ,hmmm mot yet $IOBT, lets try it again , back in at .70

0 · Reply

GCPA Dec. 22 at 1:14 PM

$IOBT Melanoma and H&N. Probably it will happens in January, before any financing news.

0 · Reply

JohnTrack Dec. 20 at 12:48 AM

$IOBT keeping tabs on sentiment!

0 · Reply

JohnTrack Dec. 19 at 10:33 PM

$IOBT Delisting notice https://www.rapidticker.com/news/iobt-sec-filing-0d3dc3

0 · Reply

Nvidioso Dec. 19 at 2:00 PM

$IOBT What kind of management has IOBT? No plan is spite of the science. To be honest, I made a huge mistake with my investment in the company. The science is not good enough to overpass the management behaviours!!

2 · Reply

yosiyosi Dec. 17 at 6:09 PM

$IOBT Stop buying scams. I bought more $ENPH shares. The managers are buying the shares + yesterday they closed a $55 million deal. I think the stock will go up 300-400%

0 · Reply

therealcryptocowboy Dec. 17 at 4:06 PM

$IOBT I’ll give this a couple more days. Losing my ass😂

1 · Reply

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

Nov 26, 2025, 10:46 AM EST - 4 weeks ago

IO Biotech Announces Participation in Upcoming December Investor Conferences

Nov 14, 2025, 8:05 AM EST - 5 weeks ago

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 12, 2025, 8:30 AM EST - 6 weeks ago

IO Biotech Announces Participation in Upcoming Investor Conferences

Nov 7, 2025, 9:00 AM EST - 6 weeks ago

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 20, 2025, 2:30 AM EDT - 2 months ago

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

Sep 29, 2025, 7:05 AM EDT - 3 months ago

IO Biotech Provides Update Following Pre-BLA Meeting with FDA

Sep 23, 2025, 8:05 AM EDT - 3 months ago

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

Sep 9, 2025, 11:41 AM EDT - 3 months ago

IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 14, 2025, 4:05 PM EDT - 4 months ago

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 12, 2025, 4:17 PM EDT - 4 months ago

IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma

Aug 11, 2025, 8:24 AM EDT - 4 months ago

IO Biotech's cancer vaccine shows improvement in late-stage study goal

Aug 11, 2025, 8:00 AM EDT - 4 months ago

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

Aug 10, 2025, 8:00 AM EDT - 4 months ago

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

May 20, 2025, 8:05 AM EDT - 7 months ago

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

May 14, 2025, 8:05 AM EDT - 8 months ago

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Apr 26, 2025, 3:05 PM EDT - 8 months ago

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 8 months ago

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

Mar 25, 2025, 4:35 PM EDT - 9 months ago

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 18, 2025, 8:00 AM EDT - 10 months ago

IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

Mar 4, 2025, 4:17 PM EST - 10 months ago

IO Biotech Reports 2024 Business Highlights

Feb 23, 2025, 12:07 PM EST - 10 months ago

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

Feb 20, 2025, 8:05 AM EST - 10 months ago

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

Feb 4, 2025, 8:05 AM EST - 11 months ago

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

Jan 9, 2025, 8:05 AM EST - 1 year ago

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

Dec 20, 2024, 8:05 AM EST - 1 year ago

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Nov 12, 2024, 7:05 AM EST - 1 year ago

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 7, 2024, 10:00 AM EST - 1 year ago

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

Oct 4, 2024, 9:00 AM EDT - 1 year ago

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 14, 2024, 2:30 AM EDT - 1 year ago

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Aug 30, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Aug 13, 2024, 7:05 AM EDT - 1 year ago

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jul 25, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

May 23, 2024, 8:30 AM EDT - 1 year ago

IO Biotech to Present at Jefferies Global Healthcare Conference

May 14, 2024, 7:55 AM EDT - 1 year ago

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

Apr 24, 2024, 4:30 PM EDT - 1 year ago

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 15, 2024, 8:30 AM EDT - 1 year ago

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

Apr 9, 2024, 12:00 PM EDT - 1 year ago

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Apr 5, 2024, 8:30 AM EDT - 1 year ago

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Mar 6, 2024, 4:11 PM EST - 1 year ago

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 5, 2024, 4:40 PM EST - 1 year ago

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Feb 26, 2024, 4:05 PM EST - 1 year ago

IO Biotech to Present at 44th Annual Cowen Health Care Conference

Jan 3, 2024, 3:04 AM EST - 2 years ago

IO Biotech: A Phase 3 Company Getting No Respect

Dec 21, 2023, 8:30 AM EST - 2 years ago

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

Nov 13, 2023, 8:12 AM EST - 2 years ago

IO Biotech Announces 2023 Third Quarter Results

Nov 13, 2023, 8:00 AM EST - 2 years ago

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Nov 10, 2023, 8:00 AM EST - 2 years ago

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Nov 1, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 23, 2023, 1:00 AM EDT - 2 years ago

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Soci

Oct 3, 2023, 4:30 PM EDT - 2 years ago

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Capitulation_0 Dec. 24 at 3:55 PM

$IOBT Seeing uptick in deals for microcaps lately. Company is running out of money, it needs to get a deal done!

0 · Reply

Msnlrainey Dec. 23 at 2:18 PM

$IOBT gotta go up to 1

0 · Reply

Love_To_Learn Dec. 22 at 10:33 PM

$IOBT $APLT *

0 · Reply

Chartwatcher1 Dec. 22 at 8:38 PM

0 · Reply

GCPA Dec. 22 at 1:14 PM

$IOBT Melanoma and H&N. Probably it will happens in January, before any financing news.

0 · Reply

JohnTrack Dec. 20 at 12:48 AM

$IOBT keeping tabs on sentiment!

0 · Reply

JohnTrack Dec. 19 at 10:33 PM

$IOBT Delisting notice https://www.rapidticker.com/news/iobt-sec-filing-0d3dc3

0 · Reply

Nvidioso Dec. 19 at 2:00 PM

2 · Reply

yosiyosi Dec. 17 at 6:09 PM

$IOBT Stop buying scams. I bought more $ENPH shares. The managers are buying the shares + yesterday they closed a $55 million deal. I think the stock will go up 300-400%

0 · Reply

therealcryptocowboy Dec. 17 at 4:06 PM

$IOBT I’ll give this a couple more days. Losing my ass😂

1 · Reply

Nvidioso Dec. 16 at 3:22 PM

$IOBT is falling down again!! No matter good news with impressive science results. The market is saying, crystal clear, management is not competent for the stock. Next!

1 · Reply

GCPA Dec. 16 at 5:35 AM

$IOBT mOS of 60 months. Better than Opdualag (51 months) and Nivolumab (34.1 months) in Relativity-047. Really strong. We can expect that the combination with Opdualag improves these 60 months of mOS. Hopefully better than the 71.9 months of Ipi+Nivo in CheckMate 67 (reminder: toxicity of Ipi+Nivo is very high; Opdualag is SOC). You can also see that DoR in CRs is 53 months. Much lower in PRs.

1 · Reply

ppl_first Dec. 16 at 1:35 AM

$IOBT is polishing the chrome on a truck with no engine. Looks impressive till you try to drive it. Shareholders keep buying gas for a rig that won’t start. FDA already said don’t file, so I’m unsure what the purpose is of the five-year charts

0 · Reply

badprecog Dec. 15 at 9:47 PM

$IOBT https://investors.iobiotech.com/news-events/news/news-details/2025/IO-Biotech-Announces-Publication-of-Five-year-Clinical-Outcomes-of-Phase-12-Trial-in-Nature-Communications/default.aspx

1 · Reply

justiceforb_85 Dec. 15 at 8:44 PM

$IOBT extremely volatile trading.

0 · Reply

Nvidioso Dec. 15 at 3:40 PM

$IOBT It is clear!! Shareholders are running away from a poor management!! Good luck $IOBT. No news regarding financial problems nor moving forward with EMA or FDA. Silence and leaving the company without management. Hopefully I am wrong!

0 · Reply

therealcryptocowboy Dec. 12 at 1:24 AM

$IOBT up to .88 overnight! LFG

0 · Reply

Chartwatcher1 Dec. 11 at 4:40 PM

$IOBT its just a matter of time... patience..

1 · Reply

AlexRo777 Dec. 11 at 3:45 PM

$IOVA we’re winning so much we’re tired of winning we can’t take it anymore, even $IOBT ytd down 5 percent that’ has a treatment for melanoma too

1 · Reply

therealcryptocowboy Dec. 10 at 1:59 AM

$IOBT I’m kind of a silent holder lol. There future could be big and we’re at .86 overnight.

0 · Reply

ppl_first Dec. 9 at 4:37 PM

$IOBT my entry is .60, does this regularly bounce that low so I can get some cheapies? Not willing to pay .83 and then have it crash in the same nanosecond back down to .60. My new rule is buy at the 1-mo low or don't buy. But if it's never getting there again then I'll have to adjust my expectations. Long term bullish. Short term hoping for a bear run.

0 · Reply

badprecog Dec. 9 at 4:01 PM

$IOBT FDA course reversal? I guess we will see?

0 · Reply

Market Cap	50.36M
Revenue (ttm)	0.00
Net Income (ttm)	-95.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	18.31

Volume	246,100
Avg Vol	2,784,946
Day's Range	N/A - N/A
Shares Out	71.95M
Stochastic %K	51%
Beta	0.47
Analysts	Sell
Price Target	$2.46